+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
P

Actively Recruiting

Researchers are studying zelicapavir, a new oral medication that stops the replication of Respiratory Syncytial Virus RSV. This Phase 2 trial is evaluating zelicapavir as a potential treatment for RSV infection in children aged 28 days to 36 months who have symptoms of RSV. The study compares zelicapavir to a placebo to assess its effects and safety in both hospitalized and non-hospitalized children. Participants are randomly assigned to receive either zelicapavir oral suspension or a matching placebo once daily for 7 days. The study monitors the time it takes for RSV symptoms to completely resolve, along with other outcomes such as the severity of symptoms, viral load changes, and any hospitalizations during the study period. These assessments occur mainly from Day 1 through Day 14, with safety followed until Day 35. During the trial, caregivers and children will be assessed regularly to track symptom resolution and viral levels using specific measurement tools. Safety is carefully monitored by recording any adverse events up to Day 35. The study spans from the initial dosing period through follow-up visits, ensuring comprehensive evaluation of zelicapavirs potential in treating RSV in young children.

Age: 28Days - 36MonthsAll GendersPhase 2
8 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
S

Actively Recruiting

Atrial fibrillation AF is a major cause of heart-related illness and death, especially among Asian patients who face higher risks of serious bleeding such as brain hemorrhage compared to non-Asians. This research, called the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation COOL-AF Phase 2, aims to study how antithrombotic medication use changes over time and how these changes affect health outcomes in people with AF. The study is observational and conducted across multiple centers in Thailand. Participants in this study have known or newly diagnosed non-valvular AF and are followed without any intervention or treatment assigned by the study. The study plans to enroll about 3680 patients over two years from 33 centers. Participants will be monitored every 6 months for up to 3 years to observe patterns of medication use, particularly warfarin and non-vitamin K antagonist oral anticoagulants NOACs, and clinical events including stroke, systemic embolism, bleeding, heart attacks, and heart failure. Throughout the study, patients will have regular check-ins every six months to track their medication usage and health status. Researchers will collect data on important outcomes such as rates of stroke, bleeding events, and quality of life. The studys primary focus is on long-term safety and effectiveness of antithrombotic treatments in this population. The total participation duration can be up to 3 years, ensuring thorough observation of clinical outcomes and treatment patterns.

Age: 18Years - 100YearsAll Genders
33 locations
P

Actively Recruiting

Researchers are evaluating doravirine as an alternative to dolutegravir in people newly diagnosed with HIV-1 infection who have not yet received treatment. This Phase III, open-label, randomized clinical trial aims to determine if doravirine combined with tenofovir and lamivudine is not less effective than dolutegravir combined with tenofovir and lamivudine or emtricitabine. The study will be conducted across multiple countries including Brazil, Cameroon, Cte dIvoire, France, Mozambique, and Thailand, enrolling 610 participants. Participants will be randomly assigned to one of two groups one receiving doravirine 100 mg plus tenofovir DF 300 mg and lamivudine 300 mg daily, and the other receiving dolutegravir 50 mg plus tenofovir DF 300 mg and either lamivudine or emtricitabine daily. The treatment period will last for 96 weeks after starting antiretroviral therapy ART, with primary assessment at week 48 to measure viral suppression. During the study, participants will undergo evaluations to monitor viral load, drug resistance, metabolic health, body weight changes, liver and kidney function, cardiovascular status, and mental health. Adherence to ART will be tracked, and blood samples will be taken to measure drug levels and immune cell counts. The research team will review virological efficacy and safety outcomes at weeks 48 and 96, supporting a comprehensive understanding of the treatments effects over nearly two years of participation.

Age: 18Years +All GendersPhase 3
19 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the efficacy, acceptability, and safety of a simplified event-driven pre-exposure prophylaxis PrEP regimen using oral TAFFTC to reduce the risk of HIV infection in HIV-uninfected cisgender men who have sex with men MSM. This Phase 3 randomized trial compares this new regimen with the existing TDFFTC regimen in Thailand and France. The study aims to determine how well emtricitabine 200 mg plus tenofovir alafenamide 25 mg, taken around sexual activity, prevents HIV compared to typical infection rates in this population. Participants will be randomly assigned to one of two groups the experimental arm receiving one tablet of TAFFTC 2 to 24 hours before sex followed by a second dose 24 hours later, or the control arm receiving two tablets of TDFFTC before sex followed by two additional tablets over the next 48 hours. In case of daily sexual activity, participants take daily doses until the last sexual encounter plus post-exposure doses. The trial will enroll participants over two years and follow them for up to three years, with study visits including physical exams and collection of blood, urine, and oral and rectal swabs. Participants will attend up to 15 visits throughout the study for monitoring and assessments. Researchers will evaluate HIV prevention efficacy, acceptability of the regimens, and safety by regularly collecting clinical and laboratory data. After study completion, participants will be referred to local HIV prevention services including PrEP. The trial includes ongoing adherence support and safety monitoring to assess the impact of these event-driven PrEP strategies in real-world settings.

Age: 18Years +MALEPhase 3
6 locations
S

Actively Recruiting

Researchers are evaluating pembrolizumab combined with carboplatin and taxane chemotherapy followed by pembrolizumab with or without maintenance sacituzumab tirumotecan sac-TMT as a first-line treatment for metastatic squamous non-small cell lung cancer NSCLC. This phase 3 study aims to determine if adding maintenance sac-TMT improves overall survival compared to pembrolizumab alone. Participants first undergo an induction phase consisting of four cycles of pembrolizumab every three weeks, carboplatin every three weeks, and either paclitaxel every three weeks or nab-paclitaxel weekly. After induction, participants are randomly assigned to receive either pembrolizumab maintenance alone or pembrolizumab combined with sac-TMT maintenance. The maintenance phase involves pembrolizumab every six weeks for up to 96 weeks and sac-TMT infusions every two weeks until discontinuation criteria are met. Throughout the study, participants will have tumor assessments, scans, and evaluations to monitor disease status, side effects, and quality of life. Researchers will measure overall survival up to approximately 50 months and progression-free survival up to 79 months, along with patient-reported symptoms such as dyspnea, cough, and chest pain. Safety monitoring includes tracking adverse events and treatment discontinuations. The total participation may last several years as long-term outcomes are assessed.

Age: 18Years +All GendersPhase 3
217 locations
G

Actively Recruiting

Researchers are conducting a Phase 23, multisite, randomized, open-label trial to study first-line treatments for non-small cell lung cancer NSCLC. This trial includes two substudies focusing on different NSCLC histological subtypes due to variations in standard chemotherapy choices. The study aims to evaluate the safety, effectiveness, and behavior of the investigational drug pumitamig combined with chemotherapy and compare it to pembrolizumab plus chemotherapy. Participants in each substudy first join a Phase 2 part where they receive one of two doses of pumitamig plus chemotherapy. In the Phase 3 part, they are randomized to receive either pumitamig plus chemotherapy or pembrolizumab plus chemotherapy. Additional participants in China will be enrolled in a Phase 2 arm to further evaluate a selected dose. Independent committees will review safety data and tumor scans throughout the study. Participants will be involved for up to 64 months, undergoing treatments through intravenous infusions. Their health will be monitored regularly to track side effects, tumor response, progression-free survival, overall survival, and quality of life through questionnaires and scans. Safety assessments include monitoring adverse events and treatment tolerance, with follow-up visits extending up to several years to assess long-term outcomes.

Age: 18Years +All GendersPhase 2Phase 3
366 locations
P

Actively Recruiting

Researchers are evaluating Remdesivir VEKLURY4 in children under two years old who are hospitalized with confirmed respiratory syncytial virus RSV infection. This Phase II, open-label, randomized controlled trial aims to assess the safety, antiviral activity, and acceptability of a five-day course of Remdesivir compared to standard care. The study focuses on how well the treatment reduces RSV replication and its safety profile in this young patient group. Participants will be randomly assigned to one of two groups one group will receive standard care alone, which may include oxygen therapy, bronchodilators, intravenous fluids, steroids, antibiotics, and treatment for underlying diseases as needed. The other group will receive Remdesivir by intravenous infusion every 24 hours for five consecutive days in addition to the standard care. Treatment doses will be based on the childs weight at the time of randomization. The study will enroll about 120 children and follow them throughout hospitalization plus a final visit 7 to 10 days after Day 6. Throughout the study, researchers will monitor participants for safety and tolerability of Remdesivir, measure RSV viral load, and assess the treatments effectiveness over one week. Assessments will include clinical observations, laboratory tests, and evaluations of respiratory status. The follow-up after hospitalization will help determine the lasting effects and acceptability of the treatment in this population.

Age: 0Days - 2YearsAll GendersPhase 2
8 locations